Company Overview and News

 
Aeon Credit gets stay of notices for extra assessment, gets new chairman

2018-05-08 thestar.com.my
In a separate filing, Aeon announced the redesignation of its director, Ng Eng Kiat, to independent and non-executive chairman of the company.

 
Foreign funds sell RM438.4mil of Malaysian shares ahead of GE14

2018-05-07 thestar.com.my
KUALA LUMPUR: Global investors turned net seller for the first time in four weeks in the penultimate week before the 14th General Election (GE14), according to MIDF Research.

 
Trading ideas: Uzma, Aeon Credit, EcoFirst, Pantech

2018-04-30 thestar.com.my
KUALA LUMPUR: Uzma Bhd , Aeon Credit Service (M) Bhd , EcoFirst Consolidated Bhd and Pantech Group Holdings Bhd are among the stocks to watch on Monday, according to JF Apex Research.

 
Aeon Credit net profit grows 13.2% in financial year 2018

2018-04-29 thestar.com.my
KUALA LUMPUR: Aeon Credit Service (M) Bhd saw its net profit grow 13.2% to RM300.06mil for the financial year ended Feb 28, 2018 (FY18), compared with RM265.03mil a year ago.

 
Bursa Malaysia stays higher at mid-morning

2018-03-30 themalaymailonline
At 11.10am, the benchmark FTSE Bursa Malaysia KLCI (FBM KLCI) was trading at 1,861.28, up 4.93 points from Thursday’s close of 1,856.35. — Picture by Azneal IshakKUALA LUMPUR, March 30 ― Bursa Malaysia stayed higher at mid-morning today on persistent buying interest in selected heavyweights, dealers said.

 
Aeon Credit files appeal against Inland Revenue Board

2018-03-07 themalaymailonline
The High Court has dismissed Aeon Credit Service's application for a judicial review of additional assessments and penalties by tax authorities. — Google image PETALING JAYA, March 7 — Aeon Credit Service (M) Bhd filed a legal appeal after its judicial review of additional assessments and penalties by tax authorities were dismissed by the High Court, The Star reported.

 
Aeon Credit files appeal over additional taxes by IRB

2018-03-06 thestar.com.my
PETALING JAYA: Aeon Credit Service (M) Bhd has filed a legal appeal after its judicial review of additional assessments and penalities by the taxman totalling RM96.81mil was dismissed by the High Court.

 
Analysts positive on Aeon’s digital transformation

2017-12-27 thestar.com.my
As expected: Aeon Credit results for the third quarter ended Nov 30 is within market expectations

 
Aeon Credit shares down despite better earnings

2017-12-22 thestar.com.my
KUALA LUMPUR: Aeon Credit Service (M) Bhd ’s share price fell 1.16% in early trade despite reporting higher net profit for the third quarter ended Nov 30, 2017.

 
Aeon Credit’s profit up on higher revenue

2017-12-22 thestar.com.my
During the quarter in review, the consumer financing provider saw revenue growing 11.4% to RM312.3mil. The company’s earnings per share (EPS) rose to 28.86 sen from 27.32 sen previously. For the cumulative nine-month period, Aeon Credit’s net profit increased 17.7% to RM217.7mil.

 
Aeon Credit sees steady growth, no material impact arising from additional tax bill

2017-12-21 thestar.com.my
KUALA LUMPUR: Aeon Credit Service Bhd sees no material impact arising from the recent additional tax bill, as the company keeps a steady growth outlook for the financial year ending Feb 28, 2018 (FY18).

 
IRB slaps Aeon Credit with RM97mil additional tax bill

2017-12-13 thestar.com.my
KUALA LUMPUR: Aeon Credit Service Bhd said it had been served with notices of additional assessment and penalties totalling almost RM97mil from the taxman.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

13h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

13h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...